54,657 Shares in iShares Biotechnology ETF $IBB Purchased by Horizon Wealth Management LLC

Horizon Wealth Management LLC purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBBFree Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 54,657 shares of the financial services provider’s stock, valued at approximately $9,224,000. iShares Biotechnology ETF comprises 1.4% of Horizon Wealth Management LLC’s portfolio, making the stock its 19th largest position. Horizon Wealth Management LLC owned approximately 0.11% of iShares Biotechnology ETF as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its position in shares of iShares Biotechnology ETF by 46,806.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 46,906 shares of the financial services provider’s stock valued at $7,927,000 after acquiring an additional 46,806 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of iShares Biotechnology ETF during the third quarter valued at about $1,907,000. Central Pacific Bank Trust Division increased its position in shares of iShares Biotechnology ETF by 296,500.0% during the fourth quarter. Central Pacific Bank Trust Division now owns 14,830 shares of the financial services provider’s stock valued at $2,503,000 after acquiring an additional 14,825 shares during the last quarter. Florin Court Capital LLP acquired a new stake in shares of iShares Biotechnology ETF during the third quarter valued at about $11,116,000. Finally, SG Americas Securities LLC increased its position in shares of iShares Biotechnology ETF by 96.3% during the third quarter. SG Americas Securities LLC now owns 28,569 shares of the financial services provider’s stock valued at $4,125,000 after acquiring an additional 14,016 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

Shares of IBB opened at $169.94 on Monday. iShares Biotechnology ETF has a 1-year low of $116.49 and a 1-year high of $179.64. The firm has a 50-day simple moving average of $169.61 and a two-hundred day simple moving average of $169.03.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Stockholders of record on Tuesday, March 17th were paid a $0.1218 dividend. The ex-dividend date of this dividend was Tuesday, March 17th. This represents a $0.49 annualized dividend and a dividend yield of 0.3%.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBFree Report).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.